Explore /
Poster
/ PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC).

PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC).

Abstract

Poster

Authors

Vincent J. Picozzi

Virginia Mason Hospital and Medical Center, Seattle, WA

Vincent J. Picozzi , Teresa Macarulla , Philip Agop Philip , Carlos Roberto Becerra , Tomislav Dragovich

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03377491

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS792)

Abstract #

TPS792

Poster Bd #

Q13

Abstract Disclosures

Similar Posters

Poster

2021 Gastrointestinal Cancers Symposium

A phase III trial of tumor-treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3.

First Author: Vincent J. Picozzi

Poster

2022 ASCO Annual Meeting

PANOVA-3: A phase 3 study of tumor-treating fields with gemcitabine and nab-paclitaxel for frontline treatment of locally advanced pancreatic adenocarcinoma.

First Author: Vincent J. Picozzi

Poster

2019 Gastrointestinal Cancers Symposium